The laboratory that markets Levothyrox, this drug indicated in the treatment of thyroid disordersEast indicted for “aggravated deception” (learn more about “the Levothyrox case“). He is accused of not having communicated enough at the time of the change of his change of formula in 2017
Remember: in 2017, Merck Laboratories began to market a “new formula” of this drug intended to treat hypothyroidism.
Issue : with the “new formula” in question, the side effects multiply – headaches, diarrhea, insomnia, dizziness, hair loss… In total, between March 2017 and April 2018, 31,000 patients reported effects more or less severe undesirable effects, attributed to this new composition of Levothyrox®.
An extension of Levothyrox demanded by the associations
The marketing of the old formula of Levothyrox was to stop at the end of September 2020. But, at the request of the French medicine agency, the Merck laboratory extended twice, until 2021, then until the end of 2022 availability of this medication for hypothyroidism. A decision awaited by several patient associations, dissatisfied with the new formula proposed since 2017.
The associations had estimated that neither the new formula of Levothyrox marketed by the Merck laboratory since 2017 nor any of the other comparable drugs on the market were suitable for certain patients.
The list of levothyroxine medications currently available is downloadable from the ANSM website.
A new health scandal?
This medication helps regulate the thyroid. 3 million French people take this treatment every day. In March 2017, a new formula was put on the French market by the Merck laboratory. The latter is problematic. Thousands of patients complain of side and adverse effects. We take stock of Top Health TV:
Source :French Association of Thyroid Patients (AFMT)
Read also :
Levothyrox: a Toulouse researcher detects “impurities” in the formula in question
Levothyrox: the new formula soon throughout Europe
Levothyrox: actress Mylène Demongeot files a complaint
-1597155771.jpg)
